693 related articles for article (PubMed ID: 32183949)
1. Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer.
Hegde S; Krisnawan VE; Herzog BH; Zuo C; Breden MA; Knolhoff BL; Hogg GD; Tang JP; Baer JM; Mpoy C; Lee KB; Alexander KA; Rogers BE; Murphy KM; Hawkins WG; Fields RC; DeSelm CJ; Schwarz JK; DeNardo DG
Cancer Cell; 2020 Mar; 37(3):289-307.e9. PubMed ID: 32183949
[TBL] [Abstract][Full Text] [Related]
2. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
3. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
4. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
[TBL] [Abstract][Full Text] [Related]
5. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.
Balachandran VP; Beatty GL; Dougan SK
Gastroenterology; 2019 May; 156(7):2056-2072. PubMed ID: 30660727
[TBL] [Abstract][Full Text] [Related]
6. The role of 2-arachidonoylglycerol in the regulation of the tumor-immune microenvironment in murine models of pancreatic cancer.
Qiu C; Yang L; Wang B; Cui L; Li C; Zhuo Y; Zhang L; Zhang S; Zhang Q; Wang X
Biomed Pharmacother; 2019 Jul; 115():108952. PubMed ID: 31078044
[TBL] [Abstract][Full Text] [Related]
7. Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC).
Chen H; Yang G; Xiao J; Zheng L; You L; Zhang T
Cancer Lett; 2020 Oct; 490():12-19. PubMed ID: 32590021
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
Sahin IH; Askan G; Hu ZI; O'Reilly EM
Ann Oncol; 2017 Dec; 28(12):2950-2961. PubMed ID: 28945842
[TBL] [Abstract][Full Text] [Related]
9. Immune Surveillance by Natural IgM Is Required for Early Neoantigen Recognition and Initiation of Adaptive Immunity.
Atif SM; Gibbings SL; Redente EF; Camp FA; Torres RM; Kedl RM; Henson PM; Jakubzick CV
Am J Respir Cell Mol Biol; 2018 Nov; 59(5):580-591. PubMed ID: 29953261
[TBL] [Abstract][Full Text] [Related]
10. Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas: The Cancer Immunity Cycle.
Kieler M; Unseld M; Bianconi D; Prager G
Pancreas; 2018 Feb; 47(2):142-157. PubMed ID: 29346215
[TBL] [Abstract][Full Text] [Related]
11. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
12. B cell-Derived IL35 Drives STAT3-Dependent CD8
Mirlekar B; Michaud D; Lee SJ; Kren NP; Harris C; Greene K; Goldman EC; Gupta GP; Fields RC; Hawkins WG; DeNardo DG; Rashid NU; Yeh JJ; McRee AJ; Vincent BG; Vignali DAA; Pylayeva-Gupta Y
Cancer Immunol Res; 2020 Mar; 8(3):292-308. PubMed ID: 32024640
[TBL] [Abstract][Full Text] [Related]
13. Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy.
Bazhin AV; Shevchenko I; Umansky V; Werner J; Karakhanova S
Cancer Immunol Immunother; 2014 Jan; 63(1):59-65. PubMed ID: 24129765
[TBL] [Abstract][Full Text] [Related]
14. Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model.
Shafiekhani S; Dehghanbanadaki H; Fatemi AS; Rahbar S; Hadjati J; Jafari AH
BMC Cancer; 2021 Nov; 21(1):1226. PubMed ID: 34781899
[TBL] [Abstract][Full Text] [Related]
15. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
Zhu Y; Knolhoff BL; Meyer MA; Nywening TM; West BL; Luo J; Wang-Gillam A; Goedegebuure SP; Linehan DC; DeNardo DG
Cancer Res; 2014 Sep; 74(18):5057-69. PubMed ID: 25082815
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: a single-center phase I/II trial.
Ogasawara M; Miyashita M; Yamagishi Y; Ota S
Ther Apher Dial; 2021 Aug; 25(4):415-424. PubMed ID: 33886156
[TBL] [Abstract][Full Text] [Related]
17. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer.
Zhao J; Wen X; Tian L; Li T; Xu C; Wen X; Melancon MP; Gupta S; Shen B; Peng W; Li C
Nat Commun; 2019 Feb; 10(1):899. PubMed ID: 30796212
[TBL] [Abstract][Full Text] [Related]
18. Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.
Kaneda MM; Cappello P; Nguyen AV; Ralainirina N; Hardamon CR; Foubert P; Schmid MC; Sun P; Mose E; Bouvet M; Lowy AM; Valasek MA; Sasik R; Novelli F; Hirsch E; Varner JA
Cancer Discov; 2016 Aug; 6(8):870-85. PubMed ID: 27179037
[TBL] [Abstract][Full Text] [Related]
19. CD90 highly expressed population harbors a stemness signature and creates an immunosuppressive niche in pancreatic cancer.
Shi J; Lu P; Shen W; He R; Yang MW; Fang Y; Sun YW; Niu N; Xue J
Cancer Lett; 2019 Jul; 453():158-169. PubMed ID: 30954649
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects.
Nsingwane Z; Candy G; Devar J; Omoshoro-Jones J; Smith M; Nweke E
Mol Biol Rep; 2020 Aug; 47(8):6269-6280. PubMed ID: 32661873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
